Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer

Randal Orchekowski, Darren Hamelinck, Lin Li, Ewa Gliwa, Matt VanBrocklin, Jorge A. Marrero, George F. Vande Woude, Ziding Feng, Randall Brand, Brian B. Haab

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

We used antibody microarrays to probe the associations of multiple serum proteins with pancreatic cancer and to explore the use of combined measurements for sample classification. Serum samples from pancreatic cancer patients (n = 61), patients with benign pancreatic disease (n = 31), and healthy control subjects (n = 50) were probed in replicate experiment sets by two-color, rolling circle amplification on microarrays containing 92 antibodies and control proteins. The antibodies that had reproducibly different binding levels between the patient classes revealed different types of alterations, reflecting inflammation (high C-reactive protein, α-1-antitrypsin, and serum amyloid A), immune response (high IgA), leakage of cell breakdown products (low plasma gelsolin), and possibly altered vitamin K usage or glucose regulation (high protein-induced vitamin K antagonist-II). The accuracy of the most significant antibody microarray measurements was confirmed through immunoblot and antigen dilution experiments. A logistic-regression algorithm distinguished the cancer samples from the healthy control samples with a 90% and 93% sensitivity and a 90% and 94% specificity in duplicate experiment sets. The cancer samples were distinguished from the benign disease samples with a 95% and 92% sensitivity and an 88% and 74% specificity in duplicate experiment sets. The classification accuracies were significantly improved over those achieved using individual antibodies. This study furthered the development of antibody microarrays for molecular profiling, provided insights into the nature of serum-protein alterations in pancreatic cancer patients, and showed the potential of combined measurements to improve sample classification accuracy.

Original languageEnglish (US)
Pages (from-to)11193-11202
Number of pages10
JournalCancer Research
Volume65
Issue number23
DOIs
StatePublished - Dec 1 2005

Fingerprint

Pancreatic Neoplasms
Blood Proteins
Antibodies
Vitamin K
Gelsolin
Serum Amyloid A Protein
Pancreatic Diseases
C-Reactive Protein
Immunoglobulin A
Neoplasms
Healthy Volunteers
Proteins
Color
Logistic Models
Inflammation
Antigens
Glucose
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. / Orchekowski, Randal; Hamelinck, Darren; Li, Lin; Gliwa, Ewa; VanBrocklin, Matt; Marrero, Jorge A.; Vande Woude, George F.; Feng, Ziding; Brand, Randall; Haab, Brian B.

In: Cancer Research, Vol. 65, No. 23, 01.12.2005, p. 11193-11202.

Research output: Contribution to journalArticle

Orchekowski, R, Hamelinck, D, Li, L, Gliwa, E, VanBrocklin, M, Marrero, JA, Vande Woude, GF, Feng, Z, Brand, R & Haab, BB 2005, 'Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer', Cancer Research, vol. 65, no. 23, pp. 11193-11202. https://doi.org/10.1158/0008-5472.CAN-05-1436
Orchekowski, Randal ; Hamelinck, Darren ; Li, Lin ; Gliwa, Ewa ; VanBrocklin, Matt ; Marrero, Jorge A. ; Vande Woude, George F. ; Feng, Ziding ; Brand, Randall ; Haab, Brian B. / Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. In: Cancer Research. 2005 ; Vol. 65, No. 23. pp. 11193-11202.
@article{47846f3ab3ea476e8412b293c60399a3,
title = "Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer",
abstract = "We used antibody microarrays to probe the associations of multiple serum proteins with pancreatic cancer and to explore the use of combined measurements for sample classification. Serum samples from pancreatic cancer patients (n = 61), patients with benign pancreatic disease (n = 31), and healthy control subjects (n = 50) were probed in replicate experiment sets by two-color, rolling circle amplification on microarrays containing 92 antibodies and control proteins. The antibodies that had reproducibly different binding levels between the patient classes revealed different types of alterations, reflecting inflammation (high C-reactive protein, α-1-antitrypsin, and serum amyloid A), immune response (high IgA), leakage of cell breakdown products (low plasma gelsolin), and possibly altered vitamin K usage or glucose regulation (high protein-induced vitamin K antagonist-II). The accuracy of the most significant antibody microarray measurements was confirmed through immunoblot and antigen dilution experiments. A logistic-regression algorithm distinguished the cancer samples from the healthy control samples with a 90{\%} and 93{\%} sensitivity and a 90{\%} and 94{\%} specificity in duplicate experiment sets. The cancer samples were distinguished from the benign disease samples with a 95{\%} and 92{\%} sensitivity and an 88{\%} and 74{\%} specificity in duplicate experiment sets. The classification accuracies were significantly improved over those achieved using individual antibodies. This study furthered the development of antibody microarrays for molecular profiling, provided insights into the nature of serum-protein alterations in pancreatic cancer patients, and showed the potential of combined measurements to improve sample classification accuracy.",
author = "Randal Orchekowski and Darren Hamelinck and Lin Li and Ewa Gliwa and Matt VanBrocklin and Marrero, {Jorge A.} and {Vande Woude}, {George F.} and Ziding Feng and Randall Brand and Haab, {Brian B.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1158/0008-5472.CAN-05-1436",
language = "English (US)",
volume = "65",
pages = "11193--11202",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer

AU - Orchekowski, Randal

AU - Hamelinck, Darren

AU - Li, Lin

AU - Gliwa, Ewa

AU - VanBrocklin, Matt

AU - Marrero, Jorge A.

AU - Vande Woude, George F.

AU - Feng, Ziding

AU - Brand, Randall

AU - Haab, Brian B.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - We used antibody microarrays to probe the associations of multiple serum proteins with pancreatic cancer and to explore the use of combined measurements for sample classification. Serum samples from pancreatic cancer patients (n = 61), patients with benign pancreatic disease (n = 31), and healthy control subjects (n = 50) were probed in replicate experiment sets by two-color, rolling circle amplification on microarrays containing 92 antibodies and control proteins. The antibodies that had reproducibly different binding levels between the patient classes revealed different types of alterations, reflecting inflammation (high C-reactive protein, α-1-antitrypsin, and serum amyloid A), immune response (high IgA), leakage of cell breakdown products (low plasma gelsolin), and possibly altered vitamin K usage or glucose regulation (high protein-induced vitamin K antagonist-II). The accuracy of the most significant antibody microarray measurements was confirmed through immunoblot and antigen dilution experiments. A logistic-regression algorithm distinguished the cancer samples from the healthy control samples with a 90% and 93% sensitivity and a 90% and 94% specificity in duplicate experiment sets. The cancer samples were distinguished from the benign disease samples with a 95% and 92% sensitivity and an 88% and 74% specificity in duplicate experiment sets. The classification accuracies were significantly improved over those achieved using individual antibodies. This study furthered the development of antibody microarrays for molecular profiling, provided insights into the nature of serum-protein alterations in pancreatic cancer patients, and showed the potential of combined measurements to improve sample classification accuracy.

AB - We used antibody microarrays to probe the associations of multiple serum proteins with pancreatic cancer and to explore the use of combined measurements for sample classification. Serum samples from pancreatic cancer patients (n = 61), patients with benign pancreatic disease (n = 31), and healthy control subjects (n = 50) were probed in replicate experiment sets by two-color, rolling circle amplification on microarrays containing 92 antibodies and control proteins. The antibodies that had reproducibly different binding levels between the patient classes revealed different types of alterations, reflecting inflammation (high C-reactive protein, α-1-antitrypsin, and serum amyloid A), immune response (high IgA), leakage of cell breakdown products (low plasma gelsolin), and possibly altered vitamin K usage or glucose regulation (high protein-induced vitamin K antagonist-II). The accuracy of the most significant antibody microarray measurements was confirmed through immunoblot and antigen dilution experiments. A logistic-regression algorithm distinguished the cancer samples from the healthy control samples with a 90% and 93% sensitivity and a 90% and 94% specificity in duplicate experiment sets. The cancer samples were distinguished from the benign disease samples with a 95% and 92% sensitivity and an 88% and 74% specificity in duplicate experiment sets. The classification accuracies were significantly improved over those achieved using individual antibodies. This study furthered the development of antibody microarrays for molecular profiling, provided insights into the nature of serum-protein alterations in pancreatic cancer patients, and showed the potential of combined measurements to improve sample classification accuracy.

UR - http://www.scopus.com/inward/record.url?scp=28244488742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28244488742&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-1436

DO - 10.1158/0008-5472.CAN-05-1436

M3 - Article

C2 - 16322270

AN - SCOPUS:28244488742

VL - 65

SP - 11193

EP - 11202

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23

ER -